
Experts at City of Hope, Simon Nazarian and Nasim Eftekhari, discussed the transformative potential of AI in cancer care.

A panelist discusses how preserving beta-cell function in type 1 diabetes (T1D) requires a multifaceted approach combining timely diagnosis, immunomodulatory therapies, optimal glycemic control and emerging technologies that can slow disease progression and improve patient outcomes.

In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.

Panelists discuss how ruxolitinib offers significant advantages in atopic dermatitis management through its targeted JAK inhibition mechanism, demonstrating rapid and sustained improvement in itch and lesions, effectiveness across various disease severities and body regions, favorable safety profile compared to systemic alternatives, and potential for reduced healthcare resource utilization over extended treatment periods.

Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more personalized, targeted approaches. This will enhance survival outcomes, refine patient selection and optimize therapy regimens.

A panelist discusses how type 1 diabetes (T1D) is frequently misdiagnosed in adults due to its overlapping clinical features with type 2 diabetes (T2D), resulting in inappropriate treatment strategies that fail to address the autoimmune destruction of beta cells and lead to accelerated disease progression and complications.

Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can enhance survival outcomes by maintaining immune system activation against cancer cells.